BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: ...
23h
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the best drug stocks to buy according to analysts. On April 7, RBC ...
The MarketWatch News Department was not involved in the creation of this content. RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today ...
—Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in ...
The company unveiled its first-quarter earnings that morning. It notched convincing beats on both the top and bottom lines. The market rewarded this performance by pushing BioCryst's share price more ...
(Reuters) -BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, strengthening its rare diseases portfolio. The offer implies ...
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the ...
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst ...
Hosted on MSN
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak
・Retail traders debated the timing and pricing of the buyout, with some expecting an all-cash offer and others speculating about various takeover scenarios. ・Skeptical users noted BioCryst’s history ...
Hosted on MSN
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased
Shares of BioCryst Pharmaceuticals, Inc. (BCRX) soared 10% in pre-market trading on Monday after the company raised its full-year guidance and reported first quarter (Q1) earnings above Wall Street ...
RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE)-- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results